131 related articles for article (PubMed ID: 20329656)
1. Comparative bioavailability of two hydrofluoroalkane formulations of formoterol fumarate both delivered by pressurised metered dose inhaler.
Po CJ; Chandran SS; Syed N; Naidu KR; Rathod M; Sule A; Lulla A; Purandare S
Arzneimittelforschung; 2010; 60(2):81-6. PubMed ID: 20329656
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A
Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant.
Rony F; Cortellini M; Guasconi A; Mathews KS; Piccinno A; Poli G; Vanhoutte F; Klein J
Pulm Pharmacol Ther; 2024 Jun; 85():102299. PubMed ID: 38663512
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
Dusser D; Vicaut E; Lefrançois G;
Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
Molimard M; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():28-34. PubMed ID: 15915010
[TBL] [Abstract][Full Text] [Related]
8. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler.
Dhillon S; Keating GM
Drugs; 2006; 66(11):1475-83; discussion 1484-5. PubMed ID: 16906779
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G
Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908
[TBL] [Abstract][Full Text] [Related]
10. Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination.
Bousquet J; Poli G; Acerbi D; Monno R; Ramael S; Nollevaux F
Clin Pharmacokinet; 2009; 48(6):347-58. PubMed ID: 19650674
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD.
Tronde A; Gillen M; Borgström L; Lötvall J; Ankerst J
J Clin Pharmacol; 2008 Nov; 48(11):1300-8. PubMed ID: 18974284
[TBL] [Abstract][Full Text] [Related]
12. Bronchodilation of formoterol administered with budesonide: device and formulation effects.
Miller CJ; Senn S; Mezzanotte WS
Contemp Clin Trials; 2008 Mar; 29(2):114-24. PubMed ID: 17625985
[TBL] [Abstract][Full Text] [Related]
13. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G
Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
[TBL] [Abstract][Full Text] [Related]
14. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients.
De Backer W; Devolder A; Poli G; Acerbi D; Monno R; Herpich C; Sommerer K; Meyer T; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):137-48. PubMed ID: 20109122
[TBL] [Abstract][Full Text] [Related]
15. Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential.
Aurivillius M; Bednarczyk A; Kokot M; Madriaga J; Mei J; Collison K; Surujbally R; Archbell J; Joshi V; Gillen M
Pulm Pharmacol Ther; 2023 Dec; 83():102245. PubMed ID: 37607661
[TBL] [Abstract][Full Text] [Related]
16. Single-dose pharmacokinetics and safety pharmacodynamics of formoterol delivered by two different dry powder inhalers.
Petzold U; Kremer HJ; Nguyen DT; Munzel U; Dietrich H; Maus J
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):309-19. PubMed ID: 18598160
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device.
Kosoglou T; Hubbell J; Johnson-Levonas AO; Yunan M; Kantesaria BS; Cutler DL
Clin Pharmacol Drug Dev; 2014 May; 3(3):222-8. PubMed ID: 27128612
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects.
Kosoglou T; Hubbell J; Kantesaria B; Hanson ME; Cutler DL
Clin Pharmacol Drug Dev; 2014 May; 3(3):229-34. PubMed ID: 27128613
[TBL] [Abstract][Full Text] [Related]
19. In vitro drug delivery performance of a new budesonide/formoterol pressurized metered-dose inhaler.
Chambers F; Ludzik A
J Aerosol Med Pulm Drug Deliv; 2009 Jun; 22(2):113-20. PubMed ID: 19422311
[TBL] [Abstract][Full Text] [Related]
20. Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI.
Singh D; Collarini S; Poli G; Acerbi D; Amadasi A; Rusca A
Br J Clin Pharmacol; 2011 Dec; 72(6):932-9. PubMed ID: 21615456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
